Among patients with active cancer and acute symptomatic VTE, the use of the LMWH tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding.

READ FULL ARTICLE Curated publisher From Medical Express